Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) saw a significant decline in short interest in September. As of September 29th, there was short interest totalling 279,863 shares, a decline of 45.3% from the September 15th total of 511,721 shares. Based on an average daily volume of 1,405,864 shares, the short-interest ratio is presently 0.2 days. Currently, 1.9% of the shares of the company are short sold.
In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were bought at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 28.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Sphera Funds Management LTD. increased its holdings in shares of Aldeyra Therapeutics by 31.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock worth $4,117,000 after buying an additional 207,431 shares during the last quarter. Perceptive Advisors LLC increased its holdings in shares of Aldeyra Therapeutics by 48.7% during the 1st quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock worth $12,897,000 after buying an additional 945,000 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $104,000. Vanguard Group Inc. increased its holdings in shares of Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares during the last quarter. Finally, Hikari Power Ltd increased its holdings in shares of Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the last quarter. Institutional investors and hedge funds own 40.32% of the company’s stock.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at 6.35 on Friday. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90. The firm’s 50-day moving average price is $7.01 and its 200-day moving average price is $5.19. The company’s market capitalization is $39.66 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. On average, analysts expect that Aldeyra Therapeutics will post ($1.47) EPS for the current fiscal year.
Several research firms recently weighed in on ALDX. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cowen and Company reiterated an “outperform” rating and set a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Cantor Fitzgerald began coverage on Aldeyra Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $22.00 target price on the stock. Finally, Canaccord Genuity reiterated a “buy” rating and set a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Aldeyra Therapeutics currently has an average rating of “Hold” and an average target price of $16.96.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/28/aldeyra-therapeutics-inc-aldx-short-interest-update.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.